RxDoctor Payments Data

Sarah Bou Nader, MD

General Practice · Leesburg, FLNPI 1356907687

Payments from drug & device makers

$833in general payments, 2019–2025

Across 43 payments — averaging $19.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$223
  • AstraZeneca$183
  • GSK$133
  • Exact Sciences$100
  • Pfizer$51
  • Astellas Pharma US Inc$39
  • plus $105 from 5 others

What the payments were for

  • Food & beverage$833100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$833 in reported general payments places this provider in the 75th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$128,293
Medicare patients
236
Services billed
6,051

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide72$94,857
EliquisApixaban72$94,282
GenvoyaElviteg/Cob/Emtri/Tenof Alafen19$77,620
Trelegy ElliptaFluticasone/Umeclidin/Vilanter56$63,412
TrulicityDulaglutide35$56,567
JanuviaSitagliptin Phosphate40$52,917
JardianceEmpagliflozin41$50,632
XareltoRivaroxaban36$35,226
MyrbetriqMirabegron42$31,606
FarxigaDapagliflozin Propanediol23$29,557
MounjaroTirzepatide24$26,959
Spiriva HandihalerTiotropium Bromide24$26,658
Breztri AerosphereBudesonide/Glycopyr/Formoterol26$25,277
SymbicortBudesonide/Formoterol Fumarate25$13,706
Stiolto RespimatTiotropium Br/Olodaterol Hcl15$13,081

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$223$94,85772 claims
PfizerEliquis$51$94,28272 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta$183$77,51295 claims
Boehringer IngelheimJardiance, Stiolto Respimat$28$63,71356 claims
GSKTrelegy Ellipta$133$63,41256 claims
Astellas Pharma US IncMyrbetriq$39$31,60642 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,901 general practice providers in Florida.

Other general practice in Leesburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →